Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma

Inclusion Criteria

• •Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1
• •Prescribed daily use of an IGCS for ≥12 weeks prior to Visit 1
• •Prescribed daily use of at least one of the following:
• •Theophylline, long acting β2-agonist (LABA), other anti-asthmatic drugs (leucotrine antagonists, inhaled anti-cholinergics, Th2 cytokine inhibitor) for at least 4 weeks prior to Visit 1 at a constant dose